目的:评估选择性激光小梁成形术(SLT)在硅油乳化相关继发性开角型青光眼(SO-OAG)中的降眼压作用。方法:采用回顾性分析,选择硅油乳化取出后未达安全眼压的SO-OAG患者120例120眼,应用360° SLT治疗。评估患者治疗1wk,1、3mo后平均眼...目的:评估选择性激光小梁成形术(SLT)在硅油乳化相关继发性开角型青光眼(SO-OAG)中的降眼压作用。方法:采用回顾性分析,选择硅油乳化取出后未达安全眼压的SO-OAG患者120例120眼,应用360° SLT治疗。评估患者治疗1wk,1、3mo后平均眼压、用药种类和成功率。结果:SLT治疗1wk,1、3mo时的平均眼压分别为 17.64± 4.52、18.96±3.33、18.03±5.69mmHg,较治疗前眼压(25.02±5.93mmHg)明显降低( P =0.002、0.04、0.03);治疗1wk,1、3mo后的平均用药种类分别为1.78±0.14、1.95±0.56、1.87±0.53种,较治疗前(3.11±0.62种)明显降低( P =0.006、0.04、0.02);治疗1wk后,显效82眼(68.3%),有效24眼(20.0%);治疗1mo后,显效74眼(61.7%),有效21眼(17.5%);治疗3mo后,显效77眼(64.2%),有效15眼(12.5%)。结论:SLT能有效降低最大耐受药物治疗不能控制眼压的SO-OAG患者的眼压。展开更多
The introduction of selective laser trabeculoplasty (SLT) provided a new choice for the reduction of intraocular pressure (IOP) in eyes with open angle glaucoma (OAG) and ocular hypertension (OHT). SLT was demonstrate...The introduction of selective laser trabeculoplasty (SLT) provided a new choice for the reduction of intraocular pressure (IOP) in eyes with open angle glaucoma (OAG) and ocular hypertension (OHT). SLT was demonstrated equally as effective as topical medical therapy and argon laser trabeculoplasty (ALT) to lower IOP. It is a potentially repeatable procedure because of the lack of coagulation damage to the trabecular meshwork (TM) and also effect in patients with previously failed ALT. SLT can be used to treat patients with OAG, pseudoexfoliation glaucoma, pigmentary glaucoma, normal-tension glaucoma, OHT, juvenile glaucoma, pseudophakic and aphakic glaucoma. Furthermore, SLT can be considered as a primary treatment option in patients who cannot tolerate or are noncompliant with medications, while not interfering with the success of future surgery. Its safety profiles include mild and transient inflammation, ocular pain and a small risk of moderate IOP elevations after the procedure. SLT is a safe and effective means of IOP reduction in eyes with OAG and OHT.展开更多
文摘目的:评估选择性激光小梁成形术(SLT)在硅油乳化相关继发性开角型青光眼(SO-OAG)中的降眼压作用。方法:采用回顾性分析,选择硅油乳化取出后未达安全眼压的SO-OAG患者120例120眼,应用360° SLT治疗。评估患者治疗1wk,1、3mo后平均眼压、用药种类和成功率。结果:SLT治疗1wk,1、3mo时的平均眼压分别为 17.64± 4.52、18.96±3.33、18.03±5.69mmHg,较治疗前眼压(25.02±5.93mmHg)明显降低( P =0.002、0.04、0.03);治疗1wk,1、3mo后的平均用药种类分别为1.78±0.14、1.95±0.56、1.87±0.53种,较治疗前(3.11±0.62种)明显降低( P =0.006、0.04、0.02);治疗1wk后,显效82眼(68.3%),有效24眼(20.0%);治疗1mo后,显效74眼(61.7%),有效21眼(17.5%);治疗3mo后,显效77眼(64.2%),有效15眼(12.5%)。结论:SLT能有效降低最大耐受药物治疗不能控制眼压的SO-OAG患者的眼压。
基金Research Fund from Health Department of Hunan Province, China (No. B2009004)Research Fund from Department of finance of Hunan Province, China (No.2008-115)
文摘The introduction of selective laser trabeculoplasty (SLT) provided a new choice for the reduction of intraocular pressure (IOP) in eyes with open angle glaucoma (OAG) and ocular hypertension (OHT). SLT was demonstrated equally as effective as topical medical therapy and argon laser trabeculoplasty (ALT) to lower IOP. It is a potentially repeatable procedure because of the lack of coagulation damage to the trabecular meshwork (TM) and also effect in patients with previously failed ALT. SLT can be used to treat patients with OAG, pseudoexfoliation glaucoma, pigmentary glaucoma, normal-tension glaucoma, OHT, juvenile glaucoma, pseudophakic and aphakic glaucoma. Furthermore, SLT can be considered as a primary treatment option in patients who cannot tolerate or are noncompliant with medications, while not interfering with the success of future surgery. Its safety profiles include mild and transient inflammation, ocular pain and a small risk of moderate IOP elevations after the procedure. SLT is a safe and effective means of IOP reduction in eyes with OAG and OHT.
